The success of the Cancer Program at Naval Medical Center, San Diego depends on the leadership of the Oncology Advisory Group (OAG), a multidisciplinary standing committee of the medical staff. The OAG includes medical representatives from all medical specialties involved in the care of the cancer patient, as well as representatives from patient administration, oncology nursing, pharmacy, tumor registry, clinical research, nutrition, social services, pastoral care, and the American Cancer Society. The OAG meets bi-monthly and is responsible for planning, initiating, stimulating and assessing all cancer related activities in the hospital, and the clinical supervision of the Tumor Registry.

Naval Medical Center, San Diego participates in the American College of Surgeons Commission on Cancer Accreditations Program. The OAG is responsible for following the standards set forth by the college. Participation as a CoC-accredited cancer program ensures that our patients receive quality care, cancer education, access to prevention and early detection programs, comprehensive care including state-of-the-art services, a multidisciplinary team coordinating the most appropriate treatment options, information on clinical trials and developing treatments, support services, a cancer registry which is vital to providing lifelong patient follow-up to monitor disease recurrence, ongoing monitoring and improvements in cancer care.

Naval Medical Center San Diego was the first Military Treatment Facility to earn the Commission on Cancer Outstanding Achievement Award, and is the only MTF to earn multiple OAAs.

A message from Dr. Preston Gable, Cancer Liaison Physician;

The Oncology Advisory Group would like to give credit to the hospital leadership—our Commander Rear Adm. C. Forrest Faison III, Deputy Commander Capt. Mark Kobelja, and the entire Executive Steering Council for providing the support and leadership necessary for us to provide truly outstanding cancer care to our military beneficiaries. Cancer care is truly a team effort—the patient is at the center, and is supported on all sides by nursing, physicians from surgery, radiology, pathology, medical oncology, radiation oncology and gynecologic oncology as well as social workers, nutritionists, physical therapy, the tumor registry, our clinical trials office, and even our local American Cancer Society. Our leadership has fostered this team approach and it has paid off—NMCSD is now a 3 time winner of the Commission on Cancer’s Outstanding Achievement Award.

As a cancer patient in our system, you will be treated like family. After all, we are one big military family. While we can’t cure everyone, we will do our best to provide professional, compassionate health care, where the patient comes first.
The Tumor Registry

The Tumor Registry, under the administrative supervision of the Patient Administration Department and the clinical supervision of the Oncology Advisory Group, manages a complete database on all patients that have been diagnosed and/or treated for a malignant disease at Naval Medical Center, San Diego. The data collected by the registry is used for the evaluation of the care of our patients. The reports created enable the command to assess the cancer treatment given and also compare our data with that of other healthcare facilities.

The Tumor Registry documents and stores all the significant elements of the patient's history and treatment, which includes demographics, anatomic site, and extent or stage of disease at the time of diagnosis. The Tumor Registry also performs follow-up annually on all cancer patients to gather survival/treatment statistics. Lifetime follow-up is essential in providing the medical staff and researchers with outcome and end results data.

The Tumor Registry assists the Oncology Advisory Group with bi-monthly meetings, attendance at Tumor Boards, Quality Improvement of the Cancer Program at NMCSD, and the survey for the American College of Surgeons Accredited Cancer Programs.

Tumor Registry Services

- Up-to-date and accurate cancer data for researchers and medical administrators for prevention and control of cancer.
- Cancer statistics for supporting evidence for medical staff, clinical trials studies, and patient care improvement.
- Custom reports of cancer data and analysis available on request for staff, residents and interns.

Oncology Advisory Group 2011 – 2012

DR G. LANNEAU, CDR, MC, USN  
CHAIR/GYNOLOGY ONCOLOGY

DR P. GABLE  
CLP/ HEMATOLOGY ONCOLOGY

DR L. RIVERA, CDR, MC, USN  
SURGICAL ONCOLOGY

DR B. NELSON, CDR, MC, USN  
PATHOLOGY

DR R. TAKESUYE, CDR, MC, USN  
RADIATION ONCOLOGY

DR C. GOEPFERT  
DIAGNOSTIC RADIOLOGY/BREAST HEALTH

DR R. HACKWORTH, LCDR, MC, USN  
PAIN MANAGEMENT

DR H. TRACY, LCDR, MC, USN  
TUMOR BOARD COORDINATOR/HEMATOLOGY ONCOLOGY

J. ALISANGCO, RN, ONP  
OUTPATIENT ONCOLOGY NURSING

C. CALLAWAY, LCDR, NC, USN  
INPATIENT ONCOLOGY NURSING

S. GHARABAGHLI, RN  
QUALITY CONTROL

R. FINKELSTEIN  
PATIENT ADMINISTRATION

H. CIARALLI, CTR  
CANCER REGISTRY

S. STODDARD  
CLINICAL RESEARCH DATA MANAGER

M. DISPENZIERI, LCSW  
OUTREACH COORDINATOR

B. MANSCHOT, LCSW  
PSYCHOSOCIAL SERVICES COORDINATOR

M. ODEN, LCDR, MSC, USN  
REHABILITATION SERVICES COORDINATOR
Cancer Screening Programs—HEDIS Initiatives

We have worked to improve breast, cervical, and colorectal cancer screening at NMCSD and to exceed national benchmarks for clinical preventive services and care. There are three areas where women can receive mammograms to be able to detect breast cancer early and treat if it is found. TOC Chula Vista, TOC Clairemont, and the Breast Health Center at NMCSD all offer mammography. Mammograms are scheduled by appointments, but each of the areas will walk-in patients if the schedule allows. In the Pharmacy, Radiology, and Lab Waiting areas, patients can pick up the "Mammo While You Wait" cards and take to the Breast Health Center, where they will try to provide walk-in mammograms if the schedule permits. NMCSD uses the Mammography Reporting System to remind patients who have had mammograms here in the past thirty days prior to their due date.

Well-woman exams and PAP tests for cervical cancer are provided through patient’s Primary Care Providers and the OB/GYN Department. In the last year we have sent reminder letters to over 3,650 women. Over 13,600 women enrolled to NMCSD have completed their cervical cancer screening exams.

A number of screening methods are available to prevent or detect colorectal cancer, such as colonoscopy, flex-sigmoidoscopy, and for those patients who have specific health conditions who should not undergo colonoscopy, NMCSD offers Colonography. Currently, clinical research and medical evidence indicates that colonoscopy is the best method to prevent colorectal cancer, however if patients elect not to have colonoscopy, test kits for stool specimens are available in each of the Primary Care Clinics. These test kits require only one specimen and may either be dropped off at any NMCSD lab or may be mailed in. Over 8,800 patients have completed their colorectal cancer screening.

NMCSD provides high quality care and has received accreditation from the Joint Commission and the American College of Surgeons. Furthermore, NMCSD’s Cancer Programs was the first Naval Medical Center to Receive an Accommodation award for excellence in cancer care. If breast cancer is detected, the Breast Health Center offers world-class coordination of care and treatments. Patients with cancer may also be referred to the Hematology/Oncology Department for multidisciplinary care and chemotherapy, General Surgery, and to Radiation Oncology. Patients are referred for enrollment in Clinical Trials that they may qualify for and Genetic Counselors are also available.
Cancer Prevention and Early Detection Programs

Cancer prevention and early detection screening programs are provided on an ongoing basis through breast, cervical, and colorectal cancer screening provided in the Primary Care Clinics, General Surgery, Gastroenterology, and Radiology Departments. The Cancer prevention and early screening programs utilize HEDIS benchmarks and uses nationally recognized evidence-based clinical practice guidelines which are posted on the Office of Clinical Quality’s SharePoint website under the Resource library.

NMCSD has a pivot table of data for the command, clinic, Medical Home Team, and to the provider level and this is accessible to all staff to review current HEDIS data and trends. Furthermore, there is a patient registry available to all clinical outpatient staff to comprehensively identify the ongoing cancer screening needs of individual patients. The Breast Health Center operates the Mammography Reporting System (MRS) which sends automated letters to patients who have had a previous mammogram within NMCSD, reminding them of the need for a mammogram thirty days prior to their due date. Additionally, there are several Women’s Health Events in the courtyard which offers walk-in Paps and mammograms for routine screening. Walk-in mammograms are available through our “Mammo While You Wait” program at the hospital Pharmacy Department for routine screening. Evening appointments are available at all three sites that provide mammograms, and pending availability of certified staff, weekend mammography clinics may be offered.

Clinical Trials

Clinical research advance science and ensures that cancer patients receive the highest possible level of care. NMCSD patients who participate in clinical trials have the opportunity to advance evidence-based medicine.

NMCSD enrolls cancer in patients in several ongoing trials, that include, but are not limited to the following;

**BREAST:** 40601(D) Randomized Phase III trial of Paclitaxel +Trastuzumab +Lapatinib vs. Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Ca

**COLORECTAL:** 80405 (D) Phase III FOLFOX Or FOLFIRI With Bev Or Cetuximab In Patients With Previously Untreated Metastatic Colorectal Adenocarcinoma

**LUNG CANCER:** 30607 (D) Phase III Double-Blind Placebo-Controlled Sunitinib as Maintenance in Advanced NSCLC

**MET BREAST, PROSTATE CANCER AND MULTIPLE MYELOMA:** 70604 Phase III Zoledronic Acid(Standard vs Longer)In Met Prostate, Met Breast, Or Multiple Myeloma

**PROSTATE/GENITOURINARY:** 90203(D) Phase III Neo-Adjuvant Docetaxel Androgen Depri-vation Prior To Radical Prostatectomy Vs Radical Prostatectomy in High Risk Prostate Ca Patients

**70807:** The Men’s Eating and Living (MEAL) Study: A Randomized Trial Of Diet to Alter Disease Progression In Prostate Cancer Patients on Active Surveillance.
In 2011 there were 786 new cancer cases accessioned into the ACTUR database. 744 cases were newly diagnosed and/or treated at Naval Medical Center, San Diego. **NOTE:** Data in this report pertains to these 744 cases only. This is a 1% decrease in the number of identified cancer cases compared to 2010. The 5 years incidence rate is illustrated in chart below.

### NMCSD Cancer Incidence 2011

In 2011 there were 786 new cancer cases accessioned into the ACTUR database. 744 cases were newly diagnosed and/or treated at Naval Medical Center, San Diego. **NOTE:** Data in this report pertains to these 744 cases only. This is a 1% decrease in the number of identified cancer cases compared to 2010. The 5 years incidence rate is illustrated in chart below.

2011 saw an increase in the number of bladder and uterine cancer cases (35 % and 32% respectfully), as well as increases in the number of breast cancer cases. There was however a fairly significant decrease in the number of reportable colorectal cancer cases as well as a decrease in lymphomas and lung cancer cases. Prostate cancer remains the most prevalent malignant disease diagnosed and/or treated at NMCSD. The table at right illustrates the top 10 sites of 2011 in comparison to the totals in 2010.

<table>
<thead>
<tr>
<th>Site</th>
<th>2011</th>
<th>2010</th>
<th>Change</th>
<th>+</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>116</td>
<td>92</td>
<td>+24</td>
<td>21%</td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>116</td>
<td>107</td>
<td>+8</td>
<td>7%</td>
<td></td>
</tr>
<tr>
<td>Bronchus &amp; Lung</td>
<td>88</td>
<td>93</td>
<td>-5</td>
<td></td>
<td>5%</td>
</tr>
<tr>
<td>Melanoma</td>
<td>45</td>
<td>42</td>
<td>+3</td>
<td>7%</td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>42</td>
<td>41</td>
<td>+1</td>
<td>2%</td>
<td></td>
</tr>
<tr>
<td>Colorectal</td>
<td>30</td>
<td>39</td>
<td>-9</td>
<td></td>
<td>23%</td>
</tr>
<tr>
<td>Lymphoma NOS</td>
<td>29</td>
<td>37</td>
<td>-8</td>
<td></td>
<td>22%</td>
</tr>
<tr>
<td>Kidney</td>
<td>28</td>
<td>29</td>
<td>-1</td>
<td></td>
<td>3%</td>
</tr>
<tr>
<td>Corpus Uteri</td>
<td>22</td>
<td>15</td>
<td>+7</td>
<td>32%</td>
<td></td>
</tr>
<tr>
<td>Bladder</td>
<td>20</td>
<td>13</td>
<td>+7</td>
<td>35%</td>
<td></td>
</tr>
</tbody>
</table>
The most prevalent incidences of cancer were Breast Cancer, Prostate Cancer, Lung Cancer, Melanoma, and Thyroid Cancer, all told these 5 cancers accounted for 56% of all reported cancers in 2011 as demonstrated in the pie charts at left.

The top chart illustrates the tops site by number of incidence, and the bottom chart illustrates the top sites by percentage.
A review of cancers by system shows that male genital cancers (including prostate) were the most prevalent incidence of cancer in 2011, followed by breast, respiratory system and digestive system. The chart at left illustrated the number of new cancers identified at NMCSD by system.

The chart to the left compares the system incidence of 2011 to 2010. The 5 most prevalent cancers show little variance in number year to year. In 2011 NMCSD saw an overall increase in male genital cancers of 6%; an increase of 21% in breast cancer; and an increase in urinary system cancers of 19%. On the flip side, respiratory system cancers decreased by 3% compared to 2010, and digestive system cancers decreased by 27%.

The Primary Site Table shown on pages 8 and 9 illustrates the cancer incidence distribution at Naval Medical Center San Diego by site, Gender Stage of disease at diagnosis and analytic (reportable to the NCDB) vs. non-analytic (non-reportable to the NCDB). The Primary Site Table is instrumental in determining cancer trends.
### 2011 Primary Site Table

<table>
<thead>
<tr>
<th>Cases</th>
<th>Sex</th>
<th>ACOS Stage @ Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Male</td>
</tr>
<tr>
<td></td>
<td>786</td>
<td>440</td>
</tr>
<tr>
<td>HEAD &amp; NECK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lip/Oral Cavity</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Tongue</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Tonsil</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Larynx</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>Sinuses</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Salivary Glands</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Other Head &amp; Neck</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>DIGESTIVE SYSTEM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esophagus</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Stomach</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Small Intestine</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Colon</td>
<td>20</td>
<td>18</td>
</tr>
<tr>
<td>Appendix</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Rectum</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Anus &amp; Anal Canal</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Liver</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Pancreas</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>RESPIRATORY SYSTEM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bronchus &amp; Lung</td>
<td>93</td>
<td>88</td>
</tr>
<tr>
<td>Pleura</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>MUSCULOSKELETAL SYSTEM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Connective &amp; Soft Tissue</td>
<td>11</td>
<td>10</td>
</tr>
<tr>
<td>HEMATOPOIETIC SYSTEM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>23</td>
<td>23</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Other Blood &amp; BM</td>
<td>9</td>
<td>9</td>
</tr>
</tbody>
</table>
### 2011 Primary Site Table

<table>
<thead>
<tr>
<th>Cases</th>
<th>Sex</th>
<th>ACoS Stage @ Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Analytic</td>
</tr>
<tr>
<td></td>
<td>786</td>
<td>744</td>
</tr>
</tbody>
</table>

**CARCINOMA OF THE SKIN**
- **Melanoma**
  - Analytic: 46
  - Male: 29
  - Female: 16
  - Stage: 14, 24, 6, 1, 0, 0, 0
- **Other Skin Carcinoma**
  - Analytic: 2
  - Male: 1
  - Female: 1
  - Stage: 0, 2, 0, 0, 0, 0, 0

**BREAST**
- **Breast**
  - Analytic: 121
  - Male: 116
  - Female: 40
  - Stage: 43, 23, 5, 5, 0, 0

**FEMALE GENITAL SYSTEM**
- **Vulva**
  - Analytic: 1
  - Male: 1
  - Female: 1
  - Stage: 0, 1, 0, 0, 0, 0, 0
- **Cervix Uteri**
  - Analytic: 10
  - Male: 9
  - Female: 1
  - Stage: 1, 8, 0, 0, 0, 0, 0
- **Corpus Uteri**
  - Analytic: 23
  - Male: 22
  - Female: 1
  - Stage: 0, 16, 1, 3, 2, 0, 0
- **Ovary**
  - Analytic: 7
  - Male: 7
  - Female: 0
  - Stage: 0, 2, 0, 4, 1, 0, 0

**MALE GENITAL SYSTEM**
- **Prostate**
  - Analytic: 134
  - Male: 116
  - Female: 18
  - Stage: 35, 11, 8, 0, 0
- **Testis**
  - Analytic: 17
  - Male: 17
  - Female: 0
  - Stage: 0, 13, 2, 2, 0, 0, 0

**URINARY SYSTEM**
- **Kidney**
  - Analytic: 29
  - Male: 20
  - Female: 8
  - Stage: 18, 2, 2, 5, 0, 0, 1
- **Renal Pelvis & Ureter**
  - Analytic: 4
  - Male: 4
  - Female: 0
  - Stage: 1, 2, 0, 0, 0, 0, 0
- **Bladder**
  - Analytic: 20
  - Male: 16
  - Female: 4
  - Stage: 9, 6, 1, 1, 3, 0, 0
- **Other Urinary**
  - Analytic: 1
  - Male: 1
  - Female: 0
  - Stage: 0, 0, 0, 1, 0, 0, 0

**EYE**
- **Eye**
  - Analytic: 1
  - Male: 1
  - Female: 0
  - Stage: 0, 0, 0, 0, 0, 0, 1

**CENTRAL NERVOUS SYSTEM**
- **Brain**
  - Analytic: 16
  - Male: 13
  - Female: 1
  - Stage: 0, 0, 0, 0, 0, 0, 0, 14
- **Other CNS**
  - Analytic: 1
  - Male: 1
  - Female: 0
  - Stage: 0, 0, 0, 0, 0, 0, 0, 1

**THYROID & ENDOCRINE GLANDS**
- **Thyroid**
  - Analytic: 45
  - Male: 15
  - Female: 27
  - Stage: 0, 35, 4, 0, 3, 0, 0
- **Adrenal Gland**
  - Analytic: 1
  - Male: 1
  - Female: 0
  - Stage: 0, 0, 0, 0, 0, 0, 0

**LYMPHATIC SYSTEM**
- **Hodgkin Disease**
  - Analytic: 5
  - Male: 4
  - Female: 2
  - Stage: 0, 0, 3, 1, 0, 0, 0
- **Non-Hodgkin Lymphoma**
  - Analytic: 25
  - Male: 18
  - Female: 7
  - Stage: 0, 10, 6, 3, 6, 0, 0

**UNKNOWN PRIMARY**
- **Unknown Primary**
  - Analytic: 14
  - Male: 8
  - Female: 6
  - Stage: 0, 0, 0, 0, 0, 0, 0, 14

**BENIGN/BORDERLINE**
- **Benign/Borderline**
  - Analytic: 28
  - Male: 18
  - Female: 10
  - Stage: 0, 0, 0, 0, 0, 0, 0, 28
In 2011 the Male to Female patient ratio was 440:304. Males made up 59% of our patient load compared to females at 41%. This is fairly consistent with historical trends both at NMCSD and nationally.

Active duty service members made up 16% of our cancer burden in 2011.

The chart at left illustrates the breakdown of our active patients by branch of service in 2011. As to be expected, of the active duty patients, active duty Navy made up two thirds of the total while active duty Marines accounted for 28%. The other uniformed services (Army, Air Force, Coast Guard) accounted for just 6% of the patient load.

This chart illustrates the gender of our active duty patients by branch of service at the time of diagnosis. As would be expected, the number of active duty navy outnumber all other branches of service combined.
The breakdown of cancer patients is illustrated in this pie chart. Caucasians make up the major of our cancers, followed by Asian-Pacific Islanders (including Filipinos). This breakdown is the historic trend at NMCSD.

NMCSD has a higher percent of API patients than is seen statewide and nationally. This is most likely due to the demographics of the military community. It should be noted that percentage for California and the U.S are from the last complete year (2010).

At left is a breakdown of 2011 cancer patients by race and gender. Note that the percentage of Asian women is higher than males, whereas males cancer patients rates are higher for all other races.
Stage of disease at diagnosis is an important prognostic indicator. The majority of cancer patients were diagnosed with Stage I disease in 2011 and about 63% of all cancer patients were diagnosed with early stage disease. The pie chart at left and the one below illustrate stage of disease by number and percentage respectfully.

A site comparison between NMCSD and projected cancers in California and Nation-wide shows very little variation. NMCSD does have a higher incidence of prostate and breast cancer in comparison to state and national figures as illustrated by the following chart. NMCSD also had a significantly lower percentage of colorectal cancer.
The chart at left breaks down primary site by gender. It should be noted that gender specific cancers i.e. Genital cancers are excluded.

The chart at left illustrates the age at diagnosis ranges of our cancer patients by system. Age parameters are:

- <30
- 30—39
- 40—49
- 50—59
- 60—69
- 70+

Median age at diagnosis is illustrated here. Respiratory system cancers had the highest median age at 68.5, while Thyroid/Endocrine Gland cancers had the lowest median age of 40. The median age of all cancer patients in 2011 was 59.